Impermanent hair loss is a well-known result of chemotherapy treatment. Though, thousands of women who have been treated with Taxotere or docetaxel report little to no hair regrowth, or non-uniform, irregular, hair regrowth, as long as six months to several years after their last chemotherapy treatment – at which time a dermatologist may identify permanent alopecia.
With or without a Taxotere alopecia diagnosis, women suffering from permanent hair loss after breast cancer chemo with Taxotere report complete baldness, bald spots, or thinning on the crown of the head, similar to male pattern baldness. To know more about taxotere, you can also consult taxotere hair loss lawsuit.
Taxotere hair loss may also consist of thinning or bald spots on the sides of the head, a receding hairline, or a drastic change in hair’s thickness. Some breast cancer survivors have reported the loss of all body hair as a result of Taxotere, containing eyelashes and eyebrows.
According to the lawsuits, Taxotere creator Sanofi-Aventis knew as early as 2005 that the drug may cause permanent alopecia in as many as 9.2% of Taxotere patients, and purposely withheld this information from the medical community and the public.
Hattie Carson was one of the first applicants to file a claim against Sanofi for failing to warn physicians or patients about the true risks of permanent or long-term alopecia. Other claims contain design and manufacturing defects, negligence, breach of express and implied warranty, and fraudulent misrepresentation.
Carson’s complaint, filed on January 22, 2016, claims that Sanofi misled the public about its risk of enduring alopecia, describing it as a “disfiguring condition, especially for women,” and that the company should have known that these risks were “far greater than with other products existing to treat the same condition.”
Her complaint seeks damages for the following injuries:
- Past and future medical expenses
- Psychological counseling and therapy expenses
- Past and future loss of earnings
- Past and future loss and impairment of earning capacity
- Permanent disfigurement including permanent alopecia
- Mental anguish
- Severe and debilitating emotional distress
- Increased risk of future harm
- Past, present, and future physical and mental pain, suffering, and discomfort
- Past, present, and future loss and impairment of the quality and enjoyment of life